GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bharat Immunologicals & Biologicals Corp Ltd (BOM:524663) » Definitions » Cyclically Adjusted Revenue per Share

Bharat Immunologicals & Biologicals (BOM:524663) Cyclically Adjusted Revenue per Share : ₹0.00 (As of Sep. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bharat Immunologicals & Biologicals's adjusted revenue per share for the three months ended in Sep. 2023 was ₹0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Bharat Immunologicals & Biologicals's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-28), Bharat Immunologicals & Biologicals's current stock price is ₹30.80. Bharat Immunologicals & Biologicals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was ₹0.00. Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bharat Immunologicals & Biologicals was 2.39. The lowest was 0.61. And the median was 1.06.


Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Bharat Immunologicals & Biologicals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Chart

Bharat Immunologicals & Biologicals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 35.79 36.59 33.60

Bharat Immunologicals & Biologicals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.59 - 33.60 - -

Competitive Comparison of Bharat Immunologicals & Biologicals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bharat Immunologicals & Biologicals's Cyclically Adjusted PS Ratio falls into.



Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bharat Immunologicals & Biologicals's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/151.4920*151.4920
=0.000

Current CPI (Sep. 2023) = 151.4920.

Bharat Immunologicals & Biologicals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 13.518 91.425 22.399
201403 23.869 91.425 39.551
201406 7.850 94.103 12.637
201409 5.636 96.780 8.822
201412 14.799 96.780 23.165
201503 5.397 97.163 8.415
201506 3.844 99.841 5.833
201509 3.088 101.753 4.597
201512 9.106 102.901 13.406
201603 13.700 102.518 20.245
201606 6.507 105.961 9.303
201609 2.561 105.961 3.661
201612 5.539 105.196 7.977
201703 23.361 105.196 33.642
201706 0.782 107.109 1.106
201709 1.221 109.021 1.697
201712 1.076 109.404 1.490
201803 4.946 109.786 6.825
201806 0.020 111.317 0.027
201809 1.082 115.142 1.424
201812 1.918 115.142 2.524
201903 16.208 118.202 20.773
201906 1.620 120.880 2.030
201909 1.832 123.175 2.253
201912 6.545 126.235 7.854
202003 5.385 124.705 6.542
202006 4.395 127.000 5.243
202009 5.903 130.118 6.873
202012 5.852 130.889 6.773
202103 3.589 131.771 4.126
202106 3.321 134.084 3.752
202109 5.726 135.847 6.385
202112 4.233 138.161 4.641
202203 4.834 138.822 5.275
202206 2.433 142.347 2.589
202209 6.098 144.661 6.386
202212 0.000 145.763 0.000
202303 1.772 146.865 1.828
202306 0.000 150.280 0.000
202309 0.000 151.492 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Bharat Immunologicals & Biologicals  (BOM:524663) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bharat Immunologicals & Biologicals was 2.39. The lowest was 0.61. And the median was 1.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bharat Immunologicals & Biologicals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Bharat Immunologicals & Biologicals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bharat Immunologicals & Biologicals (BOM:524663) Business Description

Traded in Other Exchanges
N/A
Address
Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203
Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.

Bharat Immunologicals & Biologicals (BOM:524663) Headlines

No Headlines